Evidence map›Paper›PMID 34703415›Full record

ReviewPrzeglad menopauzalny = Menopause review2021

Non-oestrogenic modalities to reverse urogenital aging.

Simone Garzon, Vasso Apostolopoulos, Lily Stojanovska, Federico Ferrari, Begum Aydogan Mathyk, Antonio Simone Laganà

Open access · goldAbstract readReview
In one paragraph

Review in Przeglad menopauzalny = Menopause review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Simone GarzonDepartment of Obstetrics and Gynaecology, AOUI Verona, University of Verona, Verona, Italy.
Vasso ApostolopoulosInstitute for Health and Sport, Victoria University, Melbourne VIC, Australia.
Lily StojanovskaInstitute for Health and Sport, Victoria University, Melbourne VIC, Australia.
Federico FerrariDepartment of Obstetrics and Gynaecology, Spedali Civili of Brescia, Brescia, Italy.
Begum Aydogan MathykHCA Healthcare/University of South Florida Morsani College of Medicine GME Consortium, Brandon Regional Hospital, Brandon, FL, USA.
Antonio Simone LaganàDepartment of Obstetrics and Gynaecology, "Filippo Del Ponte" Hospital, University of Insubria, Varese, Italy.
Victoria University · AUAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITOspedale Filippo Del Ponte Varese · ITUniversity of South Florida · USUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urogenital aging is a common process affecting all women in the post-menopausal period of their life, and it is substantially due to oestrogen deprivation after ovarian function cessation. These changes can lead to a progressive, chronic, and complex association of symptoms identified as the genitourinary syndrome of menopause, which has a significant impact on quality of life. Genitourinary syndrome and urogenital aging do not resolve spontaneously and usually recur when treatment is stopped. Therefore, appropriate long-term management is of paramount importance, and local oestrogen is the most effective treatment to reverse urogenital aging and to improve symptoms of genitourinary syndrome as replacement therapy. In some women, topical oestrogen may be inconvenient, it may not achieve complete response, or it may be contra-indicated. Several non-hormonal therapies have been investigated, but few treatments have been reported as potentially able to reverse the urogenital aging process similarly to exogenous oestrogens. Laser seems the most promising, although further studies to define its safety and efficacy are mandatory. Vitamin D and E, and phytotherapy have returned conflicting results and require further confirmation. Lifestyle modifications, physiotherapy, and electrical stimulation represent inexpensive and applicable treatments that might slow urogenital aging. Among the hormonal non-oestrogenic therapies, the use of vaginal oxytocin and dehydroepiandrosterone have been found to be effective compared to placebo, as well as the use of oral ospemifene, which partially relieves vulvovaginal atrophy.

Indexed as

genitourinary syndromenon-hormonal therapyurogenital agingvulvovaginal atrophy

Identifiers

PMID34703415
PMCPMC8525256
OpenAlexW3207722268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.